ERBB2 and breast cancer: In contrast, we found that CAF-S1 (Fig. 1d) and pCAF expression signatures (Fig. 1e) were both significantly enriched in HER2+ BC patients unresponsive to anti-HER2 mAbs and prone to relapse after treatment.